valproic acid has been researched along with Brain Stem Neoplasms in 3 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Brain Stem Neoplasms: Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the efficacy and tolerability of valproic acid (VPA) and radiation, followed by VPA and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG)." | 9.34 | A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. ( Adesina, AM; Baxter, PA; Blaney, SM; Bowers, DC; Jo, E; McNall-Knapp, RY; Mo, Q; Murray, JC; Paulino, AC; Shah, S; Su, JM, 2020) |
| "To study the efficacy and tolerability of valproic acid (VPA) and radiation, followed by VPA and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG)." | 5.34 | A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. ( Adesina, AM; Baxter, PA; Blaney, SM; Bowers, DC; Jo, E; McNall-Knapp, RY; Mo, Q; Murray, JC; Paulino, AC; Shah, S; Su, JM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Su, JM | 1 |
| Murray, JC | 1 |
| McNall-Knapp, RY | 1 |
| Bowers, DC | 1 |
| Shah, S | 1 |
| Adesina, AM | 1 |
| Paulino, AC | 1 |
| Jo, E | 1 |
| Mo, Q | 1 |
| Baxter, PA | 1 |
| Blaney, SM | 1 |
| Killick-Cole, CL | 1 |
| Singleton, WGB | 1 |
| Bienemann, AS | 1 |
| Asby, DJ | 1 |
| Wyatt, MJ | 1 |
| Boulter, LJ | 1 |
| Barua, NU | 1 |
| Gill, SS | 1 |
| Felix, FH | 1 |
| de Araujo, OL | 1 |
| da Trindade, KM | 1 |
| Trompieri, NM | 1 |
| Fontenele, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas[NCT00879437] | Phase 2 | 38 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare 1-year EFS for this trial versus historical series (ACNS0126 for high-grade gliomas; CCG-9941 for DIPG) (NCT00879437)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 12 |
| High-grade Gliomas | 24 |
complete response defined as complete disappearance of all measurable lesions,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High-grade Gliomas | 1 |
estimate the median event free survival of patients receiving protocol therapy (NCT00879437)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 7.8 |
| High-grade Gliomas | 9.1 |
median OS of patients receiving protocol therapy (NCT00879437)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 10.3 |
| High-grade Gliomas | 12.1 |
partial response defined as 51% to 99% reduction in tumor size,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 8 |
partial response defined as 51% to 99% reduction in tumor size,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High-grade Gliomas | 5 |
Document frequency of grade 2 hypertension, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 8 |
document frequency of grade 2 cystitis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 abdominal pain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment, week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 abdominal pain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 anorexia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 AST elevation, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 cough, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 fatigue, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 or higher fatigue, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 7 |
document frequency of grade 2 hypoalbuminemia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 hypoglycemia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 hypoglycemia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 intratumoral/intracranial hemorrhage, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 ocular keratitis, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 pancreatitis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 proteinuria, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 2 somnolence, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 somnolence, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 2 weight gain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 4 |
document frequency of 2 weight gain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 cellulitis, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 dehydration, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
Document frequency of grade 3 fatigue, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 hypertension, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 4 |
document frequency of grade 3 leukopenia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 lipase and amylase elevation, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 lymphopenia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 5 |
document frequency of grade 3 lymphopenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 neutropenia, graded by CTCAE v3.0, during concurrent valproic acid and radiation treatment for the first 10 weeks (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 neutropenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
Document frequency of grade 3 somonolence, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 subacute bone infarction, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 thrombocytopenia, graded according to CTCAE v3.0, during concurrent valproic acid and radiation treatment for week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 thrombocytopenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 weight gain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment during week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
Document frequency of grade 3 weight gain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 4 deep vein thrombosis, pulmonary embolism, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 4 radiation necrosis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 urinary tract infection, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
1 trial available for valproic acid and Brain Stem Neoplasms
| Article | Year |
|---|---|
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2020 |
2 other studies available for valproic acid and Brain Stem Neoplasms
| Article | Year |
|---|---|
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.
Topics: Acetylation; Adjuvants, Pharmaceutic; Animals; Anticonvulsants; Apoptosis; Brain Stem Neoplasms; Cel | 2017 |
Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Carboplatin; Child; Child, Preschool; Femal | 2014 |